Inquiry Basket
CL2A-SN-38 is a drug-linker conjugate composed of a potent DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody-drug conjugate (ADC). It has significant specific antitumor effects on a variety of human solid tumor types.
| Catalog Number | Size | Price | Quantity | ||
|---|---|---|---|---|---|
| BADC-01626 | -- | $-- | Inquiry |
CL2A-SN-38 DCA is a promising synthesized derivative of SN-38, which is recognized for its potent antineoplastic activities as the active metabolite of irinotecan, a topoisomerase-I inhibitor used primarily in the treatment of colorectal cancer. This derivative represents a significant advancement due to its enhanced solubility and stability, which are critical factors in the pharmacokinetics of anticancer agents. The CL2A modification involves the conjugation of SN-38 with a hydrophilic linker that optimizes its bioavailability, addressing the limitations posed by SN-38’s poor water solubility and challenging delivery kinetics. Such chemical modifications also aim to reduce the systemic toxicity typically associated with irinotecan therapies by improving the selective delivery of the active agent to tumor sites.
In the realm of drug discovery, CL2A-SN-38 DCA’s distinctive chemical properties offer a multifaceted approach to cancer treatment. By integrating this derivative into antibody-drug conjugates (ADCs), researchers can exploit its solubility and stability advantages. The ADC strategy leverages antibodies’ high specificity for tumor-associated antigens to deliver CL2A-SN-38 directly to cancer cells, minimizing off-target effects and maximizing therapeutic efficacy. This specificity is crucial for developing treatments that not only effectively eliminate cancer cells but also preserve healthy tissue, thus reducing the physical toll on patients undergoing chemotherapy.
Furthermore, the application of CL2A-SN-38 DCA in prodrug formulations presents another innovative pharmacological strategy. Prodrugs are inactive derivatives that convert into active drugs within the body, facilitated by enzymatic or chemical reactions. In this context, CL2A-SN-38 DCA could be strategically modified to remain dormant until it reaches a tumor microenvironment where specific enzymes activate it, thereby concentrating the cytotoxic effects predominantly within the tumor. This approach could revolutionize chemotherapy by reducing the severe side effects typically associated with broad-spectrum chemotherapy agents.
On a molecular level, the mechanism of action of CL2A-SN-38 DCA, like SN-38, involves the inhibition of topoisomerase-I, an essential enzyme that alleviates torsional strain during DNA replication by inducing reversible breaks in the DNA structure. By stabilizing the transient complex formed between DNA and topoisomerase-I, CL2A-SN-38 DCA effectively prevents religation of the breaks, leading to DNA damage, apoptosis, and cell death in rapidly dividing tumor cells. The chemical modification that defines CL2A-SN-38 DCA enhances its affinity and effectiveness in this role, presenting new opportunities in personalized cancer therapies.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
